Acta Derm Venereol:口服混合益生菌菌株可有效且安全的治疗银屑病

2020-10-03 MedSci原创 MedSci原创

这项为期12周的随机、双盲、安慰剂对照试验旨在确定益生菌混合物在减轻银屑病严重程度方面的有效性和安全性,研究结果已在线发表于Acta Derm Venereol。

这项为期12周的随机、双盲、安慰剂对照试验旨在确定益生菌混合物在减轻银屑病严重程度方面的有效性和安全性,研究结果已在线发表于Acta Derm Venereol。

研究纳入90名18-70岁的斑块状银屑病成年人,随机分为益生菌组和安慰剂组。在12周的随访中,益生菌组66.7%的患者和安慰剂组41.9%的患者的银屑病面积和严重程度指数减少高达75%(P <0.05)。在医师全球评估指数中观察到了相关的临床差异。益生菌组48.9%的人达到0或1分,而安慰剂组为30.2%。研究结束后6个月的随访结果显示,摄入益生菌混合物后,复发风险较低。

 

综上所述,肠道微生物群的分析证实了益生菌在调节微生物群组成方面的功效。

 

原始出处:

 

Vicente Navarro-LópezAsunción Martínez-Andrés, et al., Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in Patients with Psoriasis: A Randomized Controlled Clinical Trial. Acta Derm Venereol. 2019 Nov 1;99(12):1078-1084. doi: 10.2340/00015555-3305.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1850057, encodeId=0468185005ece, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Oct 19 09:45:18 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916675, encodeId=3c999166e5c9, content=我也想报名参加 把我收了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae265401553, createdName=ms4000002006802701, createdTime=Thu Jan 14 22:54:30 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889820, encodeId=1b07889820f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be3d5423199, createdName=ms2000000140331985, createdTime=Sat Oct 03 08:15:53 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
    2020-10-19 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1850057, encodeId=0468185005ece, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Oct 19 09:45:18 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916675, encodeId=3c999166e5c9, content=我也想报名参加 把我收了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae265401553, createdName=ms4000002006802701, createdTime=Thu Jan 14 22:54:30 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889820, encodeId=1b07889820f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be3d5423199, createdName=ms2000000140331985, createdTime=Sat Oct 03 08:15:53 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
    2021-01-14 ms4000002006802701

    我也想报名参加 把我收了吧

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1850057, encodeId=0468185005ece, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Oct 19 09:45:18 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916675, encodeId=3c999166e5c9, content=我也想报名参加 把我收了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae265401553, createdName=ms4000002006802701, createdTime=Thu Jan 14 22:54:30 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889820, encodeId=1b07889820f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be3d5423199, createdName=ms2000000140331985, createdTime=Sat Oct 03 08:15:53 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
    2020-10-03 ms2000000140331985

    学习了

    0

相关资讯

Hepatology: 益生菌鼠李糖乳杆菌防止肝纤维化是通过抑制肝脏胆汁酸合成和增强胆汁酸排泄

胆汁淤积性肝病的特征是肠道营养不良和过量的毒性肝胆汁酸(BAs)存积。改变肠道菌群和抑制BA合成是治疗胆汁淤积性肝病的潜在策略。

越“活”越开心,益生菌应该怎么吃?

煽动性的语言配上魔性的宣传,让消费者自掏腰包的同时,也记住了:100亿活的乳酸菌能帮助肠道做“运动”。

JAMA:补充益生菌对老年人群抗生素使用率的影响

每日补充鼠李糖乳杆菌GG和动物双歧杆菌BB-12不能显著减少老年人全因感染抗生素的使用量

Medicine:益生菌和益生元对功能性消化不良的疗效

功能性消化不良(FD)是一种功能性胃肠道疾病。有证据表明,胃肠道微生物群的紊乱可能与FD有关。我们进行了系统回顾和荟萃分析,以研究益生菌和益生元对FD的疗效。

World J Pediatr:口服益生菌能有效改善RRTI患儿肠道微生态平衡,降低RTI发生频率

复发性呼吸道感染(RRTI)是发生在学龄前儿童中的一种常见疾病。

BJOG:怀孕早期开始口服益生菌不会改变女性阴道的微生物组群

本研究旨在确定从怀孕早期开始使用口服益生菌制剂对阴道微生物群的影响。